C M Halloran

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. pmc PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial
    Christopher M Halloran
    National Institutes of Health Research Liverpool Pancreas Biomedical Research Unit and Clinical Directorate of General Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Trust and the University of Liverpool, Liverpool, L69 3GA, UK
    Trials 17:30. 2016
  2. pmc Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease
    Victoria E Shaw
    NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospital NHS Trust, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK
    Mol Cancer 13:114. 2014
  3. pmc ChroPac-trial: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial
    Markus K Diener
    University of Heidelberg, Department of General, Visceral and Transplantation Surgery, Heidelberg, Germany
    Trials 11:47. 2010
  4. ncbi request reprint Gene therapy for pancreatic cancer--current and prospective strategies
    C M Halloran
    Department of Surgery, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby Street, Liverpool, L69 3GA, UK
    Surg Oncol 9:181-91. 2000
  5. ncbi request reprint Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
    C M Halloran
    Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Liverpool, UK
    Br J Surg 95:453-9. 2008
  6. ncbi request reprint Complications of pancreatic cancer resection
    C M Halloran
    Department of Surgery, Royal Liverpool University Hospital, UK
    Dig Surg 19:138-46. 2002

Collaborators

  • J P Neoptolemos
  • M G T Raraty
  • Victoria E Shaw
  • Markus K Diener
  • Brian Lane
  • William Greenhalf
  • Robert Sutton
  • Trevor Cox
  • Claire Jenkinson
  • Joseph Tang
  • Eithne Costello
  • Meinhard Kieser
  • Thomas Bruckner
  • Jens Werner
  • Pietro Contin
  • Joachim Mossner
  • Matthias Glanemann
  • Christoph M Seiler
  • Hans Jurgen Schlitt
  • Markus W Buchler

Detail Information

Publications6

  1. pmc PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial
    Christopher M Halloran
    National Institutes of Health Research Liverpool Pancreas Biomedical Research Unit and Clinical Directorate of General Surgery, Royal Liverpool and Broadgreen University Hospitals NHS Trust and the University of Liverpool, Liverpool, L69 3GA, UK
    Trials 17:30. 2016
    ..The aim of this study is to examine if these findings remain within a randomized setting...
  2. pmc Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease
    Victoria E Shaw
    NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospital NHS Trust, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK
    Mol Cancer 13:114. 2014
    ..We investigated whether combinations of serum cytokines, used with logistic disease predictor models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC)...
  3. pmc ChroPac-trial: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial
    Markus K Diener
    University of Heidelberg, Department of General, Visceral and Transplantation Surgery, Heidelberg, Germany
    Trials 11:47. 2010
    ..A multicentre randomised trial to confirm these results is needed...
  4. ncbi request reprint Gene therapy for pancreatic cancer--current and prospective strategies
    C M Halloran
    Department of Surgery, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby Street, Liverpool, L69 3GA, UK
    Surg Oncol 9:181-91. 2000
    ..Gene delivery systems, genetic targets, and combined gene delivery with chemotherapy are discussed in the context of pancreatic cancer treatment...
  5. ncbi request reprint Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
    C M Halloran
    Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Liverpool, UK
    Br J Surg 95:453-9. 2008
    ..The present prospective study assessed the strategy of using carbohydrate antigen 19.9 (CA19.9) levels to select patients for L-LUS...
  6. ncbi request reprint Complications of pancreatic cancer resection
    C M Halloran
    Department of Surgery, Royal Liverpool University Hospital, UK
    Dig Surg 19:138-46. 2002
    ..The best way to improve outcome is to concentrate pancreatic cancer care in regional specialist centres...